Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 18 (6), 670-5

The IL-23/Th(17) Axis: Therapeutic Targets for Autoimmune Inflammation

Affiliations
Review

The IL-23/Th(17) Axis: Therapeutic Targets for Autoimmune Inflammation

Kristine Kikly et al. Curr Opin Immunol.

Erratum in

  • Curr Opin Immunol. 2007 Feb;19(1):111

Abstract

Autoimmune inflammatory responses and the diseases that develop as a consequence are now thought to be driven through a novel non-Th(1) pathway. IL-23, together with additional factors including TGF-beta1 and IL-6, collectively generate and sustain a distinct CD4(+) 'Th(17) inflammation effector' T-cell subset characterized by its production of inflammatory chemokines and cytokines, including IL-17. With this paradigm shift in understanding of autoimmune inflammation pathogenesis comes exciting opportunities to identify and to target therapeutically molecules within the IL-23/Th(17) axis that are key to disease development.

Similar articles

See all similar articles

Cited by 96 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback